

# PRECEPTORSHIP PROGRAMME

## Ovarian Cancer

Multidisciplinary management,  
standards of care and future  
perspectives

**PRAGUE**  
CZECH REPUBLIC

**21-22 APRIL 2017**

Chair Jonathan Ledermann, UK

# ESMO PRECEPTORSHIP PROGRAMME

## OVARIAN CANCER

Multidisciplinary management, standards of care  
and future perspectives

Prague, Czech Republic  
21-22 April 2017

**CHAIR:** Jonathan Ledermann, United Kingdom

**SPEAKERS:** Susana Banerjee, United Kingdom  
Nicoletta Colombo, Italy  
Christina Fotopoulou, United Kingdom  
Christian Marth, Austria  
Glenn McCluggage, United Kingdom  
Iain McNeish, United Kingdom  
Mansoor Mirza, Denmark  
Andrés M. Poveda, Spain  
Isabelle Ray-Coquard, France  
Cristiana Sessa, Switzerland

### LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of early and late stage ovarian cancer
- To understand the importance of biology and pathology of common and rare ovarian tumours
- To understand the options for treatment of recurrent disease and how treatment-decisions are made
- To understand the novel therapeutic agents being developed to treat ovarian cancer and how knowledge of genomics and molecular pathways guides drug development
- To learn about the management of patients with symptoms of the disease and the side-effects of treatment

### ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

### ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



### ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Luigi Taddei 4  
6962 Lugano - Viganello  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Friday, 21 April 2017

|                     |  |   |
|---------------------|--|---|
| 09:00-9:15<br>15'   | Welcome and introduction   | Jonathan Ledermann, UK                          |
| 09:15-10:45<br>90'  | <b>SESSION 1</b>   | <b>Chair:</b><br>Andrés M. Poveda, ES           |
| 30'                 | Pathology and biology of early epithelial ovarian cancer and rare ovarian tumours                            | Glenn McCluggage, UK                            |
| 20'                 | Surgery for early ovarian cancer - Staging and conservative surgery  | Christian Marth, AT                             |
| 20'                 | Clinical management of early ovarian cancer  | Isabelle Ray-Coquard, FR                        |
| 20'                 | BRCA mutations in ovarian cancer   | Susana Banerjee, UK                             |
| 10:45-11:15         | Coffee Break   |   |
| 11:15-12:45<br>90'  | <b>SESSION 2</b>   | <b>Chair:</b><br>Jonathan Ledermann, UK         |
| 20'                 | Biology and staging of high grade tubo-epithelial cancers  | Glenn McCluggage, UK                            |
| 20'                 | Surgery for advanced ovarian cancer  | Christina Fotopoulou, UK                        |
| 30'                 | First-line chemotherapy treatment - Current results and challenges   | Susana Banerjee, UK                             |
| 20'                 | Intraperitoneal chemotherapy - Does it have a place in treatment?  | Iain McNeish, UK                                |
| 12:45-13:45         | Lunch  |   |
| 13:45-15:55<br>130' | <b>SESSION 3</b>   | <b>Chair:</b><br>Mansoor Mirza, DK              |
| 3x10'               | <b>WORKSHOP 1:</b> Primary or delayed surgery for ovarian cancer<br>3 x Participant clinical case discussion | Christina Fotopoulou, UK<br>Christian Marth, AT |
| 20'                 | Overview of treatment of recurrent ovarian cancer  | Jonathan Ledermann, UK                          |
| 30'                 | Anti-angiogenic treatments for recurrent ovarian cancer - When, which and for how long?                      | Nicoletta Colombo, IT                           |
| 30'                 | PARP inhibitors - Current applications and future prospects  | Jonathan Ledermann, UK                          |
| 20'                 | Biology of drug resistance   | Cristiana Sessa, CH                             |
| 15:55-16:25         | Coffee Break   |   |
| 16:25-17:55<br>90'  | <b>SESSION 4</b>   | <b>Chair:</b><br>Nicoletta Colombo, IT          |
| 3x10'               | <b>WORKSHOP 2:</b> Decision-making in recurrent ovarian cancer<br>3 x Participant clinical case discussion   | Nicoletta Colombo, IT<br>Mansoor Mirza, DK      |
| 20'                 | Patient reported outcomes and quality of life  | Mansoor Mirza, DK                               |
| 20'                 | Disease assessment and novel imaging   | Andrés M. Poveda, ES                            |
| 20'                 | A clinician's guide to cancer genomics   | Cristiana Sessa, CH                             |
| 19:00               | Dinner   |   |

## Saturday, 22 April 2017

|                           |  |  |
|---------------------------|--|--|
| <b>08:30-09:30</b><br>60' | <b>SESSION 5</b>   | <b>Chair:</b><br><b>Iain McNeish, UK</b>         |
| 20'                       | Surgery for recurrent disease and palliative surgery   | Christina Fotopoulou, UK                         |
| 20'                       | Novel treatment pathways - Horizon scanning  | Cristiana Sessa, CH                              |
| 20'                       | Management of ovarian cancer in the elderly  | Susana Banerjee, UK                              |
| <b>9:30-10:00</b>         | <b>Coffee Break</b>  |  |
| <b>10:00-11:20</b><br>80' | <b>SESSION 6</b>   | <b>Chair:</b><br><b>Isabelle Ray-Coquard, FR</b> |
| 2x10'                     | <b>WORKSHOP 3:</b> Clinical trial design and endpoints<br>2 x Participant clinical case discussion | Jonathan Ledermann, UK<br>Mansoor Mirza, DK      |
| 20'                       | Clear cell cancer - Biology and therapy  | Iain McNeish, UK                                 |
| 30'                       | Immunotherapy - Current evidence and future prospects  | Christian Marth, AT                              |
| <b>11:20-12:20</b><br>60' | <b>SESSION 7</b>   | <b>Chair:</b><br><b>Cristiana Sessa, CH</b>      |
| 20'                       | Rare epithelial and non-epithelial tumours - Treatment and networks for research                   | Isabelle Ray-Coquard, FR                         |
| 20'                       | Review of 5 <sup>th</sup> Ovarian Cancer Consensus Conference, Tokyo 2015                          | Andrés M. Poveda, ES                             |
| 20'                       | Germ cell tumours - Classification and management  | Nicoletta Colombo, IT                            |
| <b>12:20-12:35</b><br>15' | <b>Conclusion and farewell</b>   | <b>Jonathan Ledermann, UK</b>                    |
| <b>12:35-13:35</b>        | <b>Lunch</b>   |  |

**Note:** Each 10 min slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion